GOLPH3 is identified as an oncoprotein potentially serving as a prognostic biomarker in various solid tumors.
A meta-analysis comprising 15 studies and 2529 cases revealed that higher levels of GOLPH3 are linked to shorter overall survival (OS) and disease-free survival (DFS).
Subgroup analysis indicated that GOLPH3 overexpression particularly correlates with worse OS in urogenital cancers, suggesting its role in predicting poor prognosis in solid tumors.